JACC Report Card Highlights Inequities in CV Care, Death Rates

As we commemorate Juneteenth 2024, JACC, the flagship journal of the American College of Cardiology, has published “Excess Cardiovascular Mortality Among Black Americans 2000-2022: A Report Card,” to highlight the persistent and tragic inequities in cardiovascular care and put in human terms the years of life lost to the Black community because of their higher cardiovascular disease death rates.

JACC Incoming Editor-in-Chief Harlan M. Krumholz, MD, SM, FACC, said, the goal of the report card is to promote accountability and catalyze action that finally addresses this national tragedy.

“Our study reveals that Black Americans, because of their higher cardiovascular mortality rates compared with White Americans, have suffered almost 800,000 excess deaths, which translates to about 24 million additional years of life lost between 2000 and 2022,” Krumholz, who is also senior author of the study and the Harold H. Hines, Jr. Professor of Medicine at Yale School of Medicine said. “This staggering figure highlights the critical need for systemic changes in addressing cardiovascular inequities.”

In an accompanying editorial, Jennifer H. Mieres, MD, FACC, chair of the ACC Diversity and Inclusion Committee and Senior Vice President, Center for Equity of Care, at Northwell Health in New Hyde Park, New York, said the report card serves as a reminder that all Americans have not benefited equally from significant advances made in the treatment and prevention of cardiovascular diseases.

“We are reminded of the stark reality that Black Americans continue to face significant disparities in cardiovascular outcomes,” Mieres said. “Bringing an equity lens to the redesign of CV health by addressing the social determinants of health and the systemic barriers that contribute to structural racism are critical for solving for cardiovascular health disparities and ensuring equity of care.”

Social determinants of health have a detrimental impact in creating barriers that prevent the most vulnerable Americans from receiving the cardiovascular care they need. The ACC has established multiple programs to address these inequities. The Internal Medicine Program introduces groups who have been historically underrepresented in cardiology to a career in cardiology by connecting them with the mentors, peer network and resources they need to understand career opportunities in the field and be better prepared to address the unique and diverse health care challenges their patients face.

The Clinical Trials Research (CTR) program is intended to increase the number of individuals historically underrepresented in cardiology who serve as leaders in cardiovascular clinical trials research to ensure diversity of thought, experience and perspective, and ensure that the evidence base includes data more closely reflecting the demographics of actual cardiovascular patients.

SourceACC

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”